flowpra® screening class i and ii Search Results


monoclonal antibody against mhc class molecules  (Becton Dickinson)
90
Becton Dickinson monoclonal antibody against mhc class molecules
Monoclonal Antibody Against Mhc Class Molecules, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/flowpra%C2%AE+screening+class+i+and+ii/monoclonal+antibody+against+mhc+class+molecules/pm10587647-151-0-10
Average 90 stars, based on 1 article reviews
monoclonal antibody against mhc class molecules - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
mhc class i molecules  (Kerkau Manufacturing)
90
Kerkau Manufacturing mhc class i molecules
Mhc Class I Molecules, supplied by Kerkau Manufacturing, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/flowpra%C2%AE+screening+class+i+and+ii/mhc+class+i+molecules/pm15916790-123-25-29
Average 90 stars, based on 1 article reviews
mhc class i molecules - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
mhc class i molecules  (Feto Maternal and GenetYX Center)
90
Feto Maternal and GenetYX Center mhc class i molecules
Mhc Class I Molecules, supplied by Feto Maternal and GenetYX Center, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/flowpra%C2%AE+screening+class+i+and+ii/mhc+class+i+molecules/10__1111_slash_imm__12002-19316-6-22
Average 90 stars, based on 1 article reviews
mhc class i molecules - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
hla class i abc  (Proteintech)
95
Proteintech hla class i abc
CDK4/6 inhibitor and EGFR inhibitor increase MHC-I expression by targeting E2F1/SEC61G axis. (A) “Transcription Factor Target” analysis for 2275 co-expressed genes related to SEC61G in HNSCC (Head and Neck Squamous Cell Carcinoma (TCGA, Firehose Legacy)) through webgestalt approach. (B) The correlation between the expression of SEC61G and EGFR in HNSC normal and HNSC tumor based on TCGA-HNSC database. (C) Combination Palbociclib and Cetuximab in Patient-Derived Tumor Xenograft (PDX) model related to hypopharyngeal squamous cell carcinoma. Hypopharyngeal cancer PDX models were treated with control, Palbociclib (100 mg/kg/day), Cetuximab (1 mg/week) or Cetuximab plus Palbociclib for 28 days (n = 6 per group). The growth curves of xenografts are shown. After 28 days, the mice were killed, and tumors were dissected, weighed and photographed. One-way ANOVA and Tukey’s multiple comparisons test. * p < .05, ** p < .01, *** p < .001. Pal, Palbociclib; Cet, Cetuximab; ns, not significant. (D) Immunohistochemistry staining of E2F1, SEC61G, and <t>HLA</t> class I <t>ABC</t> (MHC-I) in PDX models after treatments. Pal, Palbociclib treatment mouse; Cet, Cetuximab treatment mouse; Pal + Cet, Palbociclib plus Cetuximab treatment mouse.
Hla Class I Abc, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/flowpra%C2%AE+screening+class+i+and+ii/HLA+class+I+ABC+Antibody/pmc09880322-64-3-8
Average 95 stars, based on 1 article reviews
hla class i abc - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
propranolol hydrochloride  (Enamine Ltd)
99
Enamine Ltd propranolol hydrochloride
CDK4/6 inhibitor and EGFR inhibitor increase MHC-I expression by targeting E2F1/SEC61G axis. (A) “Transcription Factor Target” analysis for 2275 co-expressed genes related to SEC61G in HNSCC (Head and Neck Squamous Cell Carcinoma (TCGA, Firehose Legacy)) through webgestalt approach. (B) The correlation between the expression of SEC61G and EGFR in HNSC normal and HNSC tumor based on TCGA-HNSC database. (C) Combination Palbociclib and Cetuximab in Patient-Derived Tumor Xenograft (PDX) model related to hypopharyngeal squamous cell carcinoma. Hypopharyngeal cancer PDX models were treated with control, Palbociclib (100 mg/kg/day), Cetuximab (1 mg/week) or Cetuximab plus Palbociclib for 28 days (n = 6 per group). The growth curves of xenografts are shown. After 28 days, the mice were killed, and tumors were dissected, weighed and photographed. One-way ANOVA and Tukey’s multiple comparisons test. * p < .05, ** p < .01, *** p < .001. Pal, Palbociclib; Cet, Cetuximab; ns, not significant. (D) Immunohistochemistry staining of E2F1, SEC61G, and <t>HLA</t> class I <t>ABC</t> (MHC-I) in PDX models after treatments. Pal, Palbociclib treatment mouse; Cet, Cetuximab treatment mouse; Pal + Cet, Palbociclib plus Cetuximab treatment mouse.
Propranolol Hydrochloride, supplied by Enamine Ltd, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/flowpra%C2%AE+screening+class+i+and+ii/Propranolol+hydrochloride/custom%40en300-16419%4010%2E22270%2Fjddt%2Ev15i3%2E7044
Average 99 stars, based on 1 article reviews
propranolol hydrochloride - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
mhc class i molecules  (Verlag GmbH)
90
Verlag GmbH mhc class i molecules
CDK4/6 inhibitor and EGFR inhibitor increase MHC-I expression by targeting E2F1/SEC61G axis. (A) “Transcription Factor Target” analysis for 2275 co-expressed genes related to SEC61G in HNSCC (Head and Neck Squamous Cell Carcinoma (TCGA, Firehose Legacy)) through webgestalt approach. (B) The correlation between the expression of SEC61G and EGFR in HNSC normal and HNSC tumor based on TCGA-HNSC database. (C) Combination Palbociclib and Cetuximab in Patient-Derived Tumor Xenograft (PDX) model related to hypopharyngeal squamous cell carcinoma. Hypopharyngeal cancer PDX models were treated with control, Palbociclib (100 mg/kg/day), Cetuximab (1 mg/week) or Cetuximab plus Palbociclib for 28 days (n = 6 per group). The growth curves of xenografts are shown. After 28 days, the mice were killed, and tumors were dissected, weighed and photographed. One-way ANOVA and Tukey’s multiple comparisons test. * p < .05, ** p < .01, *** p < .001. Pal, Palbociclib; Cet, Cetuximab; ns, not significant. (D) Immunohistochemistry staining of E2F1, SEC61G, and <t>HLA</t> class I <t>ABC</t> (MHC-I) in PDX models after treatments. Pal, Palbociclib treatment mouse; Cet, Cetuximab treatment mouse; Pal + Cet, Palbociclib plus Cetuximab treatment mouse.
Mhc Class I Molecules, supplied by Verlag GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/flowpra%C2%AE+screening+class+i+and+ii/mhc+class+ii+molecules/10__1002_slash_eji__201090053-5-12-5
Average 90 stars, based on 1 article reviews
mhc class i molecules - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
classical mhc class i molecules  (Santa Cruz Biotechnology)
95
Santa Cruz Biotechnology classical mhc class i molecules
CDK4/6 inhibitor and EGFR inhibitor increase MHC-I expression by targeting E2F1/SEC61G axis. (A) “Transcription Factor Target” analysis for 2275 co-expressed genes related to SEC61G in HNSCC (Head and Neck Squamous Cell Carcinoma (TCGA, Firehose Legacy)) through webgestalt approach. (B) The correlation between the expression of SEC61G and EGFR in HNSC normal and HNSC tumor based on TCGA-HNSC database. (C) Combination Palbociclib and Cetuximab in Patient-Derived Tumor Xenograft (PDX) model related to hypopharyngeal squamous cell carcinoma. Hypopharyngeal cancer PDX models were treated with control, Palbociclib (100 mg/kg/day), Cetuximab (1 mg/week) or Cetuximab plus Palbociclib for 28 days (n = 6 per group). The growth curves of xenografts are shown. After 28 days, the mice were killed, and tumors were dissected, weighed and photographed. One-way ANOVA and Tukey’s multiple comparisons test. * p < .05, ** p < .01, *** p < .001. Pal, Palbociclib; Cet, Cetuximab; ns, not significant. (D) Immunohistochemistry staining of E2F1, SEC61G, and <t>HLA</t> class I <t>ABC</t> (MHC-I) in PDX models after treatments. Pal, Palbociclib treatment mouse; Cet, Cetuximab treatment mouse; Pal + Cet, Palbociclib plus Cetuximab treatment mouse.
Classical Mhc Class I Molecules, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/flowpra%C2%AE+screening+class+i+and+ii/MHC+class+I+Antibody/pmc03667415-77-10-18
Average 95 stars, based on 1 article reviews
classical mhc class i molecules - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
polymorphic mhc class i molecules  (Tajima Shoji Co Ltd)
86
Tajima Shoji Co Ltd polymorphic mhc class i molecules
CDK4/6 inhibitor and EGFR inhibitor increase MHC-I expression by targeting E2F1/SEC61G axis. (A) “Transcription Factor Target” analysis for 2275 co-expressed genes related to SEC61G in HNSCC (Head and Neck Squamous Cell Carcinoma (TCGA, Firehose Legacy)) through webgestalt approach. (B) The correlation between the expression of SEC61G and EGFR in HNSC normal and HNSC tumor based on TCGA-HNSC database. (C) Combination Palbociclib and Cetuximab in Patient-Derived Tumor Xenograft (PDX) model related to hypopharyngeal squamous cell carcinoma. Hypopharyngeal cancer PDX models were treated with control, Palbociclib (100 mg/kg/day), Cetuximab (1 mg/week) or Cetuximab plus Palbociclib for 28 days (n = 6 per group). The growth curves of xenografts are shown. After 28 days, the mice were killed, and tumors were dissected, weighed and photographed. One-way ANOVA and Tukey’s multiple comparisons test. * p < .05, ** p < .01, *** p < .001. Pal, Palbociclib; Cet, Cetuximab; ns, not significant. (D) Immunohistochemistry staining of E2F1, SEC61G, and <t>HLA</t> class I <t>ABC</t> (MHC-I) in PDX models after treatments. Pal, Palbociclib treatment mouse; Cet, Cetuximab treatment mouse; Pal + Cet, Palbociclib plus Cetuximab treatment mouse.
Polymorphic Mhc Class I Molecules, supplied by Tajima Shoji Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/flowpra%C2%AE+screening+class+i+and+ii/class+i+mhc+molecules+polymorphic/pm11148219-180-2-10
Average 86 stars, based on 1 article reviews
polymorphic mhc class i molecules - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
classical mhc class i molecules  (Feto Maternal and GenetYX Center)
90
Feto Maternal and GenetYX Center classical mhc class i molecules
CDK4/6 inhibitor and EGFR inhibitor increase MHC-I expression by targeting E2F1/SEC61G axis. (A) “Transcription Factor Target” analysis for 2275 co-expressed genes related to SEC61G in HNSCC (Head and Neck Squamous Cell Carcinoma (TCGA, Firehose Legacy)) through webgestalt approach. (B) The correlation between the expression of SEC61G and EGFR in HNSC normal and HNSC tumor based on TCGA-HNSC database. (C) Combination Palbociclib and Cetuximab in Patient-Derived Tumor Xenograft (PDX) model related to hypopharyngeal squamous cell carcinoma. Hypopharyngeal cancer PDX models were treated with control, Palbociclib (100 mg/kg/day), Cetuximab (1 mg/week) or Cetuximab plus Palbociclib for 28 days (n = 6 per group). The growth curves of xenografts are shown. After 28 days, the mice were killed, and tumors were dissected, weighed and photographed. One-way ANOVA and Tukey’s multiple comparisons test. * p < .05, ** p < .01, *** p < .001. Pal, Palbociclib; Cet, Cetuximab; ns, not significant. (D) Immunohistochemistry staining of E2F1, SEC61G, and <t>HLA</t> class I <t>ABC</t> (MHC-I) in PDX models after treatments. Pal, Palbociclib treatment mouse; Cet, Cetuximab treatment mouse; Pal + Cet, Palbociclib plus Cetuximab treatment mouse.
Classical Mhc Class I Molecules, supplied by Feto Maternal and GenetYX Center, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/flowpra%C2%AE+screening+class+i+and+ii/mhc+molecules/pmc02196038-68-3-13
Average 90 stars, based on 1 article reviews
classical mhc class i molecules - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
shed mhc-i molecules  (NeuroRepair)
90
NeuroRepair shed mhc-i molecules
CDK4/6 inhibitor and EGFR inhibitor increase MHC-I expression by targeting E2F1/SEC61G axis. (A) “Transcription Factor Target” analysis for 2275 co-expressed genes related to SEC61G in HNSCC (Head and Neck Squamous Cell Carcinoma (TCGA, Firehose Legacy)) through webgestalt approach. (B) The correlation between the expression of SEC61G and EGFR in HNSC normal and HNSC tumor based on TCGA-HNSC database. (C) Combination Palbociclib and Cetuximab in Patient-Derived Tumor Xenograft (PDX) model related to hypopharyngeal squamous cell carcinoma. Hypopharyngeal cancer PDX models were treated with control, Palbociclib (100 mg/kg/day), Cetuximab (1 mg/week) or Cetuximab plus Palbociclib for 28 days (n = 6 per group). The growth curves of xenografts are shown. After 28 days, the mice were killed, and tumors were dissected, weighed and photographed. One-way ANOVA and Tukey’s multiple comparisons test. * p < .05, ** p < .01, *** p < .001. Pal, Palbociclib; Cet, Cetuximab; ns, not significant. (D) Immunohistochemistry staining of E2F1, SEC61G, and <t>HLA</t> class I <t>ABC</t> (MHC-I) in PDX models after treatments. Pal, Palbociclib treatment mouse; Cet, Cetuximab treatment mouse; Pal + Cet, Palbociclib plus Cetuximab treatment mouse.
Shed Mhc I Molecules, supplied by NeuroRepair, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/flowpra%C2%AE+screening+class+i+and+ii/shed+mhc+i+molecules/pmc07723833-211-7-15
Average 90 stars, based on 1 article reviews
shed mhc-i molecules - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
mhc class i molecules  (Shanghai Zerun Biotechnology Co)
90
Shanghai Zerun Biotechnology Co mhc class i molecules
CDK4/6 inhibitor and EGFR inhibitor increase MHC-I expression by targeting E2F1/SEC61G axis. (A) “Transcription Factor Target” analysis for 2275 co-expressed genes related to SEC61G in HNSCC (Head and Neck Squamous Cell Carcinoma (TCGA, Firehose Legacy)) through webgestalt approach. (B) The correlation between the expression of SEC61G and EGFR in HNSC normal and HNSC tumor based on TCGA-HNSC database. (C) Combination Palbociclib and Cetuximab in Patient-Derived Tumor Xenograft (PDX) model related to hypopharyngeal squamous cell carcinoma. Hypopharyngeal cancer PDX models were treated with control, Palbociclib (100 mg/kg/day), Cetuximab (1 mg/week) or Cetuximab plus Palbociclib for 28 days (n = 6 per group). The growth curves of xenografts are shown. After 28 days, the mice were killed, and tumors were dissected, weighed and photographed. One-way ANOVA and Tukey’s multiple comparisons test. * p < .05, ** p < .01, *** p < .001. Pal, Palbociclib; Cet, Cetuximab; ns, not significant. (D) Immunohistochemistry staining of E2F1, SEC61G, and <t>HLA</t> class I <t>ABC</t> (MHC-I) in PDX models after treatments. Pal, Palbociclib treatment mouse; Cet, Cetuximab treatment mouse; Pal + Cet, Palbociclib plus Cetuximab treatment mouse.
Mhc Class I Molecules, supplied by Shanghai Zerun Biotechnology Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/flowpra%C2%AE+screening+class+i+and+ii/mhc+class+i+molecules/pm22469208-12-15-29
Average 90 stars, based on 1 article reviews
mhc class i molecules - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
anti mhc class i  (fluidigm)
93
fluidigm anti mhc class i
List of metal-labeled antibodies used for mass cytometry
Anti Mhc Class I, supplied by fluidigm, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/flowpra%C2%AE+screening+class+i+and+ii/Anti-Mouse+MHC+Class+I+(28-14-8)-144Nd/pmc10485166-36-0-4
Average 93 stars, based on 1 article reviews
anti mhc class i - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

Image Search Results


CDK4/6 inhibitor and EGFR inhibitor increase MHC-I expression by targeting E2F1/SEC61G axis. (A) “Transcription Factor Target” analysis for 2275 co-expressed genes related to SEC61G in HNSCC (Head and Neck Squamous Cell Carcinoma (TCGA, Firehose Legacy)) through webgestalt approach. (B) The correlation between the expression of SEC61G and EGFR in HNSC normal and HNSC tumor based on TCGA-HNSC database. (C) Combination Palbociclib and Cetuximab in Patient-Derived Tumor Xenograft (PDX) model related to hypopharyngeal squamous cell carcinoma. Hypopharyngeal cancer PDX models were treated with control, Palbociclib (100 mg/kg/day), Cetuximab (1 mg/week) or Cetuximab plus Palbociclib for 28 days (n = 6 per group). The growth curves of xenografts are shown. After 28 days, the mice were killed, and tumors were dissected, weighed and photographed. One-way ANOVA and Tukey’s multiple comparisons test. * p < .05, ** p < .01, *** p < .001. Pal, Palbociclib; Cet, Cetuximab; ns, not significant. (D) Immunohistochemistry staining of E2F1, SEC61G, and HLA class I ABC (MHC-I) in PDX models after treatments. Pal, Palbociclib treatment mouse; Cet, Cetuximab treatment mouse; Pal + Cet, Palbociclib plus Cetuximab treatment mouse.

Journal: Frontiers in Pharmacology

Article Title: Increased response to TPF chemotherapy promotes immune escape in hypopharyngeal squamous cell carcinoma

doi: 10.3389/fphar.2022.1097197

Figure Lengend Snippet: CDK4/6 inhibitor and EGFR inhibitor increase MHC-I expression by targeting E2F1/SEC61G axis. (A) “Transcription Factor Target” analysis for 2275 co-expressed genes related to SEC61G in HNSCC (Head and Neck Squamous Cell Carcinoma (TCGA, Firehose Legacy)) through webgestalt approach. (B) The correlation between the expression of SEC61G and EGFR in HNSC normal and HNSC tumor based on TCGA-HNSC database. (C) Combination Palbociclib and Cetuximab in Patient-Derived Tumor Xenograft (PDX) model related to hypopharyngeal squamous cell carcinoma. Hypopharyngeal cancer PDX models were treated with control, Palbociclib (100 mg/kg/day), Cetuximab (1 mg/week) or Cetuximab plus Palbociclib for 28 days (n = 6 per group). The growth curves of xenografts are shown. After 28 days, the mice were killed, and tumors were dissected, weighed and photographed. One-way ANOVA and Tukey’s multiple comparisons test. * p < .05, ** p < .01, *** p < .001. Pal, Palbociclib; Cet, Cetuximab; ns, not significant. (D) Immunohistochemistry staining of E2F1, SEC61G, and HLA class I ABC (MHC-I) in PDX models after treatments. Pal, Palbociclib treatment mouse; Cet, Cetuximab treatment mouse; Pal + Cet, Palbociclib plus Cetuximab treatment mouse.

Article Snippet: SEC61G (11147-2-AP) and HLA class I ABC (15240-1-AP): Proteintech.

Techniques: Expressing, Derivative Assay, Control, Immunohistochemistry, Staining

List of metal-labeled antibodies used for mass cytometry

Journal: iScience

Article Title: Temporal and spatial dynamics of immune cells in spontaneous liver transplant tolerance

doi: 10.1016/j.isci.2023.107691

Figure Lengend Snippet: List of metal-labeled antibodies used for mass cytometry

Article Snippet: Anti-MHC Class I , Fluidigm , 3144016C.

Techniques:

Journal: iScience

Article Title: Temporal and spatial dynamics of immune cells in spontaneous liver transplant tolerance

doi: 10.1016/j.isci.2023.107691

Figure Lengend Snippet:

Article Snippet: Anti-MHC Class I , Fluidigm , 3144016C.

Techniques: Transplantation Assay, Recombinant, Staining, Cell Isolation, Software, Cytometry, Flow Cytometry